Online inquiry

IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13002MR)

This product GTTS-WQ13002MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CSF3R gene. The antibody can be applied in Neutropenia research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000760.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1441
UniProt ID Q99062
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13002MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14859MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ5728MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ10801MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA M777-16-3
GTTS-WQ15015MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ6608MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DC-1728001
GTTS-WQ4715MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BOS161721
GTTS-WQ10170MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LC1004-002
GTTS-WQ10373MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY2062430
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW